Berenberg initiates coverage on Pharmanutra stock with Buy rating, EUR85 target

Berenberg has initiated coverage on Pharmanutra SpA (BIT:PHN) with a Buy rating and an EUR85.00 price target, implying over 100% potential upside. The positive outlook is attributed to the company's leadership in oral iron supplements, its patented Sucrosomial technology, and a doctor-led business model, with significant "transformational growth" anticipated from strategic international expansion into the U.S. and China within three years, complementing its resilient European operations.

Analysis

Berenberg has initiated coverage on Pharmanutra SpA (BIT:PHN) with a 'Buy' rating and an EUR85.00 price target, implying a potential upside of over 100% from current levels. The investment thesis is anchored in the company's leadership position in the oral iron supplement market, which is sustained by its patented Sucrosomial technology and a unique doctor-led business model. Berenberg highlights this as a hybrid platform that merges pharmaceutical-grade standards with the scalability of nutraceuticals, creating a significant competitive advantage. The primary catalyst for future value creation is the company's strategic expansion into the United States and China, where management anticipates significant sales growth within three years. This international push is expected to deliver 'transformational growth,' complementing what the research firm already views as a resilient European business franchise. The upcoming quarters will be critical for providing investors with greater visibility on the execution and initial success of these key international initiatives.

Key Decisions for Investors

• Given Berenberg's 'Buy' initiation and a price target suggesting over 100% upside, investors may consider this a strong signal to evaluate initiating or adding to a position in Pharmanutra SpA.
• Investors should closely monitor upcoming quarterly results for tangible progress and initial sales figures from the U.S. and China expansion, as these are the primary catalysts for the 'transformational growth' thesis.
• While the core European business is described as resilient, the investment case is heavily weighted on the successful execution of international growth; any delays or underperformance in these new markets presents a significant risk to achieving the projected upside.